- Conditions
- Food Insecurity
- Interventions
- Food Security Screening & Referral Program
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 51
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- Tirzepatide, Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 142
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 123 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- ALN-CIDEB, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Tucson, Arizona
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Interventions
- LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
- Diagnostic Test · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25), Metabolic Syndrome
- Interventions
- Paso Program
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
- Interventions
- Thermoacoustic Enhanced Ultrasound
- Device
- Lead sponsor
- Endra Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
- Drug · Diagnostic Test · Dietary Supplement + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Efinopegdutide, Placebo
- Combination Product
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight (BMI > 25)
- Interventions
- bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester), Placebo
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
- Interventions
- ALN-HSD, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 61
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 47 more
- Conditions
- NASH/MASH, NAFLD/MASLD
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
- Conditions
- Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
- Interventions
- BMN 255, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
- Conditions
- Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Placebo (PB)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • Los Angeles, California • Miami, Florida + 2 more
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Pegozafermin, Placebo
- Biological · Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Interventions
- LY3849891, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Orange, California • Rialto, California + 8 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Pegozafermin, Placebo
- Biological · Other
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Food Insecurity
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Interventions
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
- Procedure · Drug · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Rialto, California • Tampa, Florida • San Antonio, Texas
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Interventions
- EHR alert
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Type 2 Diabetes, Liver Disease
- Interventions
- Behavioral Treatment
- Device
- Lead sponsor
- SIPPA Solutions INC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Jamaica, New York
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
- Interventions
- AI-Enabled Identification (EchoNet-Liver)
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • Pleasanton, California + 2 more